RecruitingNot applicableNCT03588286
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Studying Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Western Sydney Local Health District
- Principal Investigator
- Study Principal Investigator Study Principal InvestigatorWestern Sydney Local Health District
- Intervention
- Electrophysiology study (EPS)(procedure)
- Enrollment
- 1058 target
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2014 – 2029
Study locations (30)
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Canberra Hospital, Garran, Australian Capital Territory, Australia
- Nepean Hospital, Kingswood, New South Wales, Australia
- John Hunter Hospital, New Lambton Heights, New South Wales, Australia
- Prince of Wales Hospital, Randwick, New South Wales, Australia
- Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
- Wollongong Hospital, Wollongong, New South Wales, Australia
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
- Carins Hospital, Cairns, Queensland, Australia
- The Prince Charles Hospital, Chermside, Queensland, Australia
- The Townsville Hospital, Douglas, Queensland, Australia
- Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
- Gold Coast University Hospital, Southport, Queensland, Australia
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03588286 on ClinicalTrials.govOther trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07217548Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease PatientsOhio State University
- RECRUITINGPHASE2NCT07236190Biomarker-based Trial of NPC-1 for Alzheimer's PathologyMassachusetts General Hospital
- RECRUITINGPHASE1NCT06911008MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid CancersMayo Clinic
- ENROLLING BY INVITATIONNCT07331831Research on Attitudes, Confidence, and Practical Skills in Performing Cardiopulmonary Resuscitation and Automated External Defibrillation After Completing a Course Based on the European Resuscitation Council ModelFirst Three Minutes Foundation
- RECRUITINGNANCT07084142Developing a Digital Aid to Improve ICD DecisionsStanford University
- RECRUITINGNANCT06896825Increasing Physical Activity Through Social Support and Stress ResilienceArizona State University
- RECRUITINGNANCT07563660FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))Istanbul University - Cerrahpasa
- RECRUITINGPHASE1NCT06506461Gene Editing For Sickle Cell DiseaseSt. Jude Children's Research Hospital
See all trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome →